Re: Huge Profits Predicted For Pfizer 100,000 Billion Revenue In One Year
Sharon’s Opinion: Huge under-reporting of side effects (some permanent debilitating damage) due to vaccine cocktails and singular vaccines (if that even exists any more) led to early approval and subsequent fears of retribution directed at health care institutions who reported anything that could not be proven.
Doctors and health care workers are dismissing symptoms as mentally-charged or generated by anti-vaccine supporters. Anti-vaxxers they call them. Who comes up with these nicknames as if it’s all a big joke?
They were right to question, and when not given provable answers, they were right to refuse. That provable demand works on both sides of the street.
To suggest that seniors, the most medically vulnerable in all societies (no it’s not children), should be given robust vaccines, which means supercharged, overly potent vaccines, when their systems are too fragile to accommodate them is attempted murder. You can’t give seniors or children more powerful vaccines with more destructive side effects, than you give healthy adults. It’s not scientifically logical to smack the elders and tap the middleagers.
To tell the seniors they need more powerful vaccines, when everybody knows that elders in every other category of medication are given a lower dose, not a higher than anybody else dose is suspect to say the least. WAKE UP pharmaceuticals. Stop the torture of seniors. I’m looking at a holocaust here.
Pharmaceutical companies are making huge profits. If they’re so worried about people not getting vaccinated, then give it for free – to everybody. Obviously they live for their bottom line, not to make your lives better. Oh, they may keep you alive, but in vaccine hell for the rest of one’s life is not a better life.
What the world needs is evolutionary science, not revolutionary science. Revolutions kill.
Scientists are lying about the data. The way they use statistics to generate the result they want should be criminal. Law makers don’t understand science, that’s why the so-called science industry gets away with murder for profit.
People can handle the truth; it’s the lies and misrepresentations told to scare them into taking something that is going to make wealthy people even wealthier, that people can’t handle. JUST TELL THE TRUTH. It’s their life, not yours to manipulate for profit or prejudice.
Pfizer sees $10 billion-$15 billion in potential revenue from mRNA vaccines by 2030
(Reuters) -Pfizer Inc said on Monday annual revenue from its mRNA vaccine portfolio could reach $10 billion to $15 billion by 2030, alleviating fears of a sharp hit to its topline from an expected decline in COVID vaccine demand and patent expirations.
Shares of the New York City-based company rose nearly 2% to $52.59 during afternoon trade and helped lift U.S. stock indexes higher.
The company’s revenue is expected to top $100 billion this year– more than double the pre-pandemic level – helped by strong demand for its COVID-19 vaccine and oral treatment Paxlovid.
In November, Pfizer had raised its forecast for 2022 sales of its COVID-19 vaccine by $2 billion to $34 billion.
But COVID-related sales are expected to drop sharply over the next few years, and Pfizer also faces the loss of patent protections for some big-selling drugs after 2025, such as cancer treatment Ibrance and arthritis drug Xeljanz.
Pfizer expects to lose $17 billion in annual sales between 2025 and 2030 due to the patent expirations, Chief Commercial Officer Angela Hwang said in an investor presentation, where the company provided revenue expectations for its drugs and vaccines.
The company has been investing heavily into its mRNA pipeline and said the manufacturing capacity for Comirnaty, its COVID-19 vaccine developed with German partner BioNTech SE, leaves it uniquely positioned to deliver other mRNA shots globally.
Analysts expect COVID-19 vaccine revenues to drop sharply beginning in 2023 and see sales of Pfizer’s Comirnaty at around $6.7 billion in 2027, according to Refinitiv.
Pfizer did not provide a breakdown of sales expectations from different mRNA vaccine, but said sales from its respiratory syncytial virus (RSV) vaccine candidate, to be launched in 2023, could peak in 2027 and reach more than $2 billion.
(Reporting by Bhanvi Satija in Bengaluru and Michael Erman in New Jersey; Editing by Shinjini Ganguli)